Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model

Neoplasia

Volumn 11, Issue 8, 2009, Pages 812-822

  Hofmann, Matthias ^a,b   McCormack, Emmet ^b,c   Mujić, Maja ^b,c   Roßberg, Maila ^a   Bernd, August ^a   Bereiter Hahn, Jürgen ^a   Gjertsen, Bjørn Tore ^b,c   Wiig, Helge ^b   Kippenberger, Stefan ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DEXTRAN; HUMAN SERUM ALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL TRANSPORT; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; MACROMOLECULE; MONOTHERAPY; MOUSE; NONHUMAN; ONCOTIC PRESSURE; PRIORITY JOURNAL; RAT; TISSUE PRESSURE; VULVA CARCINOMA;

EID: 67650469703     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09662     Document Type: Article

References (42)

1. Jain RK (2001). Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J Control Release 74, 7-25.
2. Young JS, Lumsden CE, and Stalker AL (1950). The significance of the tissue pressure of normal testicular and of neoplastic (Brown-Pearce carcinoma) tissue in rabbit. J Pathol Bacteriol 62, 313-333.
3. Wiig H, Tveit E, Hultborn R, Reed RK, and Weiss L (1982). Interstitial fluid pressure in DMBA-induced rat mammary tumours. Scan J Clin Lab Invest 42, 159-164.
4. Jain RK and Gerlowski LE (1986). Extravascular transport in normal and tumor tissues. Crit Rev Oncol Hematol 5, 115-170.
5. Heldin CH, Rubin K, Pietras K, and Östman A (2004). High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 4, 806-813.
6. Jain RK (1987). Transport of molecules across tumor vasculature. Cancer Metastasis Rev 6, 559-593.
7. Jain RK (1987). Transport of molecules in the tumor interstitium: a review. Cancer Res 47, 3039-3051.
8. Tufto I and Rofstad EK (1999). Interstitial fluid pressure and capillary diameter distribution in human melanoma xenografts. Microvasc Res 58, 205-214.
9. Carmeliet P and Jain RK (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257.
10. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, and Jain RK (2000). Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 60, 4324-4327.
11. Baxter LT and Jain RK (1989). Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res 37, 77-104.
12. Jain RK (1998). The next frontier of molecular medicine: delivery of therapeutics. Nat Med 4, 655-657.
13. Hofmann M, Guschel M, Bernd A, Bereiter-Hahn J, Kaufmann R, Tandi C, Wiig H, and Kippenberger S (2006). Lowering of tumor interstitial fluid pressure reduces tumor cell proliferation in a xenograft tumor model. Neoplasia 8, 89-95.
14. Hofmann M, Schultz M, Bernd A, Bereiter-Hahn J, Kaufmann R, and Kippenberger S (2007). Long-term lowering of tumor interstitial fluid pressure reduces Ki-67 expression. J Biomech 40, 2324-2329.
15. Starling EH (1896). On absorption of fluids from connective tissue spaces. J Physiol 19, 312-326.
16. Wiig H, Aukland K, and Tenstad O (2003). Isolation of interstitial fluid from rat mammary tumors by a centrifugation method. Am J Physiol Heart Circ Physiol 284, H416-H424.
17. Wiig H, Reed RK, and Aukland K (1981). Micropuncture measurement of interstitial fluid pressure in rat subcutis and skeletal muscle: comparison to wickin-needle technique. Microvasc Res 21, 308-319.
18. Wiig H, Halleland EG, Fjaertoft M, and Aukland K (1988). Measurement of colloid osmotic pressure in submicrolitre samples. Acta Physiol Scand 132, 445-452.
19. McCormack E, Micklem DR, Pindard LE, Silden E, Gallant P, Belenkov A, Lorens JB, and Gjertsen BT (2007). In vivo optical imaging of acute myeloid leukemia by green fluorescence protein: time-domain autofluorescence decoupling, fluorophore quantification, and localization. Mol Imaging 6, 193-204.
20. Alves F, Dullin C, Napp J, Missbach-Guentner J, Jannasch K, Mathejczyk J, Pardo LA, Stühmer W, and Tietze LF (2009). Concept of a selective tumour therapy and its evaluation by near-infrared fluorescence imaging and flat-panel volume computed tomography in mice. Eur J Radiol 70, 286-293.
21. Christian NA, Benencia F, Milone MC, Li G, Frail PR, Therien MJ, Coukos G, and Hammer DA (2009). In vivo dendritic cell tracking using fluorescence lifetime imaging and near-infrared-emissive polymersomes. Mol Imaging Biol 11, 167-177.
22. Lakowicz JR, Szmacinski H, Nowaczyk K, and Johnson ML (1992). Fluorescence lifetime imaging of calcium using Quin-2. Cell Calcium 13, 131-147.
23. Szmacinski H and Lakowicz JR (1993). Optical measurements of pH using fluorescence lifetimes and phase-modulation fluorometry. Anal Chem 65, 1668-1674.
24. Boucher Y and Jain RK (1992). Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 52, 5110-5114.
25. Lee I, Boucher Y, Demhartner TJ, and Jain RK (1994). Changes in tumour blood flow, oxgenation and interstitial fluid pressure induced by pentoxifylline. Br J Cancer 69, 492-496.
26. Brekken C and De Lange Davies C (1998). Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. Cancer Lett 131, 65-70.
27. Salnikov A, Iversen VV, Koisti M, Sundberg C, Johansson L, Stuhr LB, Sjöquist M, Ahlström H, Reed RK, and Rubin K (2003). Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J 17, 1756-1758.
28. Boucher Y, Kirkwood JM, Opacic D, Desantis M, and Jain RK (1991). Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 50, 6691-6694.
29. Gutmann R, Leunig M, Feyh J, Goetz AE, Messmer K, Kastenbauer E, and Jain RK (1992). Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res 52, 1993-1995.
30. Nathanson SD and Nelson L (1994). Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma. Ann Surg Oncol 1, 333-338.
31. Guyton and Hall (2005). Textbook of Medical Physiology, 11th ed., Elsevier Ltd, Oxford, UK.
32. Solbach C, Sterner-Kock A, Roller M, Schnürch HG, Stegmüller M, Caspar-Bell G, Schumm-Draeger PM, Kaufmann M, and Knecht R (2002). Antitumor effect of Mab EMD 55900 depends on EGF-R expression and histopathology. Neoplasia 4, 237-242.
33. Lee CG, Heijn M, Di Tomaso E, Griffon-Etienne C, Ankukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, et al. (2000). Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60, 5565-5570.
34. Pietras K, Östmann A, Sjöquist M, Buchdunger E, Reed RK, Heldin CH, and Rubin K (2001). Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61, 2929-2934.
35. Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, et al. (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10, 145-147.
36. Ogawa Y, Kawamura T, Furuhashi M, Tsukamoto K, and Shimada S (2008). Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate. J Dermatol Sci 51, 190-199.
37. Inai T, Mancuso M, Hahizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, et al. (2004). Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165, 35-52.
38. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, and Jain RK (2004). Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64, 3731-3736.
39. Pietras K, Rubin K, Sjöblom T, Buchdunger E, Sjöquist M, Heldin C-H, and Östman A (2002). Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62, 5476-5484.
40. Pietras K (2004). Increasing tumor uptake of anticancer drugs with imatinib. Semin Oncol 31, 18-23.
41. Baranowska-Kortylewicz J, Abe M, Pietras K, Kortylewicz ZP, Kurizaki T, Nearman J, Paulsson J, Mosley RL, Enke CA, and Östman A (2005). Effect of platelet-derived growth factor receptor-β inhibition with STI571 on radioimmunotherapy. Cancer Res 65, 7824-7831.
42. Vlahovic G, Rabbani ZN, Herndon I, Dewhirstz MW, and Vujaskovic Z (2006). Treatment with imatinib in NSCLC is associated with the decrease of phosphorylated PDGFR-β and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer 95, 1013-1019.